Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Dr Elena de Vita

Back to Search
Zhang L, Lovell S, De Vita E, Jagtap PKA, Lucy D, Grocin AG, Kjær S, Borg A et al. ( 2022 ) . A KLK6 Activity-Based Probe Reveals a Role for KLK6 Activity in Pancreatic Cancer Cell Invasion . Journal of the American Chemical Society vol. 144 , ( 49 ) 22493 - 22504 .
Jamshidiha M, Lanyon-Hogg T, Sutherell CL, Craven GB, Tersa M, De Vita E, Brustur D, Pérez-Dorado I et al. ( 2022 ) . Identification of the first structurally validated covalent ligands of the small GTPase RAB27A . RSC Medicinal Chemistry vol. 13 , ( 2 ) 150 - 155 .
Zhang Q, Kounde CS, Mondal M, Greenfield JL, Baker JR, Kotelnikov S, Ignatov M, Tinworth CP et al. ( 2022 ) . Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs) . Chemical Communications vol. 58 , ( 78 ) 10933 - 10936 .
Yoon H, Triplet EM, Simon WL, Choi C, Kleppe LS, De Vita E, Miller AK, Scarisbrick IA ( 2021 ) . Blocking Kallikrein 6 promotes developmental myelination . Glia vol. 70 , ( 3 ) 430 - 450 .
Santamaria S, Buemi F, Nuti E, Cuffaro D, De Vita E, Tuccinardi T, Rossello A, Howell S et al. ( 2021 ) . Development of a fluorogenic ADAMTS-7 substrate . Journal of Enzyme Inhibition and Medicinal Chemistry vol. 36 , ( 1 ) 2160 - 2169 .
De Vita E, Lucy D, Tate EW ( 2021 ) . Beyond targeted protein degradation: LD·ATTECs clear cellular lipid droplets . Cell Research vol. 31 , ( 9 ) 945 - 946 .
Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, Williams ED, Engelsberger E et al. ( 2021 ) . A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer . Journal of the American Chemical Society vol. 143 , ( 23 ) 8911 - 8924 .
Maneiro M, De Vita E, Conole D, Kounde CS, Zhang Q, Tate EW ( 2021 ) . PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs . vol. 60 , Elsevier
De Vita E ( 2020 ) . 10 years into the resurgence of covalent drugs . Future Medicinal Chemistry vol. 13 , ( 2 ) 193 - 210 .
De Vita E, Maneiro M, Tate EW ( 2020 ) . The Missing Link between (Un)druggable and Degradable KRAS . ACS Central Science vol. 6 , ( 8 ) 1281 - 1284 .
De Vita E, Smits N, van den Hurk H, Beck EM, Hewitt J, Baillie G, Russell E, Pannifer A et al. ( 2019 ) . Synthesis and Structure‐Activity Relationships of N‐(4‐Benzamidino)‐Oxazolidinones: Potent and Selective Inhibitors of Kallikrein‐Related Peptidase 6 . ChemMedChem vol. 15 , ( 1 ) 79 - 95 .
D'Andrea F, Nuti E, Becherini S, Cuffaro D, Husanu E, Camodeca C, De Vita E, Zocchi MR et al. ( 2019 ) . Design and Synthesis of Ionic Liquid‐Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI‐Coated Gold Nanoparticles . ChemMedChem vol. 14 , ( 6 ) 686 - 698 .
De Vita E, Schüler P, Lovell S, Lohbeck J, Kullmann S, Rabinovich E, Sananes A, Heßling B et al. ( 2018 ) . Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity . Journal of Medicinal Chemistry vol. 61 , ( 19 ) 8859 - 8874 .
Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES, Papo N ( 2018 ) . A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering . Journal of Biological Chemistry vol. 293 , ( 33 ) 12663 - 12680 .
Longuespée R, Wefers AK, De Vita E, Miller AK, Reuss DE, Wick W, Herold-Mende C, Kriegsmann M et al. ( 2018 ) . Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry . Acta Neuropathologica Communications vol. 6 , ( 1 )
Back to Search